Recce Pharmaceuticals Ltd Price Chart
Recce Pharmaceuticals Ltd RCE.XA Financial and Trading Overview
| Recce Pharmaceuticals Ltd stock price | 0.59 AUD |
| Previous Close | 0.54 AUD |
| Open | 0.55 AUD |
| Bid | 0.5 AUD x N/A |
| Ask | 0.56 AUD x N/A |
| Day's Range | 0.5 - 0.57 AUD |
| 52 Week Range | 0.49 - 0.93 AUD |
| Volume | 58.68K AUD |
| Avg. Volume | 14.77K AUD |
| Market Cap | N/A |
| Beta (5Y Monthly) | 1.106896 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.053 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RCE.XA Valuation Measures
| Enterprise Value | 98M AUD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 76.071434 |
| Enterprise Value/Revenue | 31.768 |
| Enterprise Value/EBITDA | -6.416 |
Trading Information
Recce Pharmaceuticals Ltd Stock Price History
| Beta (5Y Monthly) | 1.106896 |
| 52-Week Change | -9.32% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.93 AUD |
| 52 Week Low | 0.49 AUD |
| 50-Day Moving Average | 0.6 AUD |
| 200-Day Moving Average | 0.67 AUD |
RCE.XA Share Statistics
| Avg. Volume (3 month) | 14.77K AUD |
| Avg. Daily Volume (10-Days) | 15.39K AUD |
| Shares Outstanding | N/A |
| Float | 106.88M |
| Short Ratio | N/A |
| % Held by Insiders | 42.50% |
| % Held by Institutions | 3.05% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -495.64% |
| Gross Margin | -161.50% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -98.52% |
| Return on Equity (ttm) | -181.71% |
Income Statement
| Revenue (ttm) | 3.08M AUD |
| Revenue Per Share (ttm) | 0.02 AUD |
| Quarterly Revenue Growth (yoy) | -63.60% |
| Gross Profit (ttm) | -3245992 AUD |
| EBITDA | -15274781 AUD |
| Net Income Avi to Common (ttm) | -15225219 AUD |
| Diluted EPS (ttm) | -0.053 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.85M AUD |
| Total Cash Per Share (mrq) | 0.01 AUD |
| Total Debt (mrq) | 127.46K AUD |
| Total Debt/Equity (mrq) | 10.3 AUD |
| Current Ratio (mrq) | 1.85 |
| Book Value Per Share (mrq) | 0.007 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14466550 AUD |
| Levered Free Cash Flow (ttm) | -8628034 AUD |
Profile of Recce Pharmaceuticals Ltd
| Country | Australia |
| State | NSW |
| City | Sydney |
| Address | Aurora Place |
| ZIP | 2000 |
| Phone | 61 2 9256 2571 |
| Website | https://www.recce.com.au |
| Industry | |
| Sector(s) | |
| Full Time Employees | N/A |
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Q&A For Recce Pharmaceuticals Ltd Stock
What is a current RCE.XA stock price?
Recce Pharmaceuticals Ltd RCE.XA stock price today per share is 0.59 AUD.
How to purchase Recce Pharmaceuticals Ltd stock?
You can buy RCE.XA shares on the Cboe AU exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Recce Pharmaceuticals Ltd?
The stock symbol or ticker of Recce Pharmaceuticals Ltd is RCE.XA.
How many shares does Recce Pharmaceuticals Ltd have in circulation?
The max supply of Recce Pharmaceuticals Ltd shares is 0.
What is Recce Pharmaceuticals Ltd Price to Earnings Ratio (PE Ratio)?
Recce Pharmaceuticals Ltd PE Ratio is now.
What was Recce Pharmaceuticals Ltd earnings per share over the trailing 12 months (TTM)?
Recce Pharmaceuticals Ltd EPS is -0.053 AUD over the trailing 12 months.